Halozyme Therapeutic (HALO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Sales | 290,084 | 231,353 | 195,879 | 230,039 | 216,033 |
| Cost of Goods | 49,426 | 39,607 | 28,329 | 52,298 | 54,823 |
| Gross Profit | 240,658 | 191,746 | 167,550 | 177,741 | 161,210 |
| Operating Expenses | 77,887 | 75,118 | 72,337 | 77,004 | 73,754 |
| Operating Income | 163,197 | 117,235 | 95,542 | 101,035 | 88,279 |
| Interest Expense | 4,524 | 4,524 | 4,507 | 5,220 | 4,505 |
| Other Income | 6,474 | 5,032 | 4,993 | 5,360 | 17,986 |
| Pre-tax Income | 165,147 | 117,743 | 96,028 | 101,175 | 101,760 |
| Income Tax | 28,136 | 24,498 | 19,205 | 15,787 | 19,923 |
| Net Income Continuous | 137,011 | 93,245 | 76,823 | 85,388 | 81,837 |
| Net Income | $137,011 | $93,245 | $76,823 | $85,388 | $81,837 |
| EPS Basic Total Ops | 1.08 | 0.73 | 0.61 | 0.65 | 0.62 |
| EPS Basic Continuous Ops | 1.08 | 0.73 | 0.61 | 0.65 | 0.62 |
| EPS Diluted Total Ops | 1.05 | 0.72 | 0.60 | 0.64 | 0.61 |
| EPS Diluted Continuous Ops | 1.05 | 0.72 | 0.60 | 0.64 | 0.61 |
| EPS Diluted Before Non-Recurring Items | 1.17 | 0.85 | 0.71 | N/A | N/A |
| EBITDA(a) | $182,277 | $136,367 | $115,213 | $121,067 | $111,693 |